Novartis to Pay $150M to Ionis, Akcea for Drug to Slow Heart Disease - Xconomy

Novartis to Pay $150M to Ionis, Akcea for Drug to Slow Heart Disease  Xconomy

Novartis has agreed to pay $150 million to Ionis Pharmaceuticals and Boston-based Akcea Therapeutics for the rights to a clinical-stage drug meant to.